Anti-viral drug remdesivir reduces risk of hospitalization in high-risk ...

1

View
comments

Remdesivir reduces the risk of hospitalization and medical visits due to COVID-19 in high-risk patients, new data suggest. 

California-based Gilead Sciences Inc, the maker of the antiviral drug, published the results of its Phase III clinical trial on Wednesday.

Researchers found patients treated with remdesivir were 87 percent less likely to be hospitalized and 81 less likely to require a medical visit than those who were given a placebo.

The team says the findings shows that remdesivir, the only drug fully approved to treat severely ill coronavirus patients, can also be used for those who are at-high risk of becoming seriously ill - but are still early on in their infection.